About the Centre
Our Team
University of Oxford
Cassandra Adams | Translational Scientist, CMD |
Paul Brennan | PI, Medicinal Chemistry, CMD |
Charlotte Deane | PI, Department of Statistics |
Brian Marsden | PI, Research Informatics, CMD |
Alejo Nevado-Holgado | PI, Department of Psychiatry |
Cornelia van Duijn | PI, Nuffield Dept of Population Health |
Wyatt Yue | PI, Metabolic and Rare Diseases, CMD |
King Abdulaziz University
Dr Hani Choudhry | hchoudhry@kau.edu.sa |
Dr Ashwag Albukhari | aalbukhari@kau.edu.sa |
Dr Wesam Hussein Abdulaal | whabdulaal@kau.edu.sa |
Dr Majid Almansouri | malmansouri@kau.edu.sa |
Dr Hisham Altayeb | hdemmahom@kau.edu.sa |
Dr Diena Mohammedallam Almasri | dalmasri@kau.edu.sa |
Dr Abdelsattar Mansour Ebeid Omar | asmansour@kau.edu.sa |
Dr Mohammad Imran Khan | mikhan@kau.edu.sa |
Dr Majed Felemban | maafelemban1@kau.edu.sa |
Dr Mazin Abdulaziz Zamzami | mzamzami@kau.edu.sa |
Dr Mahmoud Alhosin | malhaseen@kau.edu.sa |
Dr Mahmoud Ragab | mragab@kau.edu.sa |
Dr Salman Bakr Hosawi | shosawi@kau.edu.sa |
Dr Haneen Reda Banjar | hrbanjar@kau.edu.sa |
Dr Amer Assiri | ahasseri@kau.edu.sa |
Dr Mahmoud Abdelkhalek Elfaky | melfaky@kau.edu.sa |
Dr Fatemah Omar Kamel | foakamel@kau.edu.sa |
Dr Faisal A Alzahrani | faahalzahrani@kau.edu.sa |
Dr Moustafa E. El-Araby | madaoud@kau.edu.sa |
Dr Nofe Ateq Alganmi | nalghanimi@kau.edu.sa |
Dr Aliaa Amr Alamoudi | aaalamoudi2@kau.edu.sa |
Dr Mustafa Adnan Zeyadi | mzyadi@kau.edu.sa |
Dr Ehab Atif Abozinadah | eabozinadah@kau.edu.sa |
Dr Othman A. Baothman | oabaothman@kau.edu.sa |
Dr Khalidah Khalid Nasser | kknasser@kau.edu.sa |
Mr. Samer Mohammed Alamoudi | smsalamoudi@kau.edu.sa |
Our Workflow
WP1: Clinical landscape in KSA
Lead: Dr Hani Choudhry
Key Activities: Identifying, collating and assessing PROMS and EHR from patients in KSA, as well as other datasets
Milestone: Clinical survey report of the disease landscape in KSA
WP2: Artificial Intelligence in novel target discovery
Leads: Prof Alejo Nevado-Holgado and Prof Cornelia van Duijn
Key Activities: Apply AI to genomic, transcriptomic and proteomic profiles of KSA patients to nominate targets. Validate targets with EHRs epidemiology
Milestone: Identification and validation of novel drug targets
WP3: Target biological characterisation
Lead: Prof Wyatt Yue
Key Activities: Investigation of pathways and mechanisms of identified genetic driver of disease using biochemical, structural and cellular approaches.
Milestone: Characterisation of biology of novel targets and creation of assays
WP4: Drug design and discovery
Lead: Prof Paul Brennan
Key Activities: Chemical tool compound design to be guided by pharmacophoric information, computational chemistry and knowledge of metabolic liabilities.
Milestone: Identification of potential binding locations
WP5: AI methodology for drug design
Lead: Prof. Brian Marsden and Prof. Charlotte Deane
Key Activities: Utilizing machine learning, structural bioinformatics and artificial intelligence, plus natural language processing (NLP) holds the promise of highly optimised and efficient novel drug design
Target Milestone: AI-led optimisation of novel drug design